A non-randomised open-label exploratory ‘window of opportunity’ study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer
This study demonstrated that TG02/GM-CSF was well tolerated and induced a vaccine specific systemic immune response in the majority of patients. Low numbers limit conclusive clinical outcome reporting. High PD-1 expression on post-treatment TILs encourages the addition of an immune checkpoint inhibitor to TG02 and potentially other studies of peptide vaccines in future studies.
Authors
- Magnus Jäderberg (ORCID: https://orcid.org/0000-0003-1917-1996)
- John Raymond Zalcberg (ORCID: https://orcid.org/0000-0002-6624-0782)
- Matthew Burge (ORCID: https://orcid.org/0000-0003-2562-7806)
- Catherine Mitchell (ORCID: https://orcid.org/0000-0001-5596-9511)
- Alexander G. Heriot (ORCID: https://orcid.org/0000-0001-9846-8776)
- Łukasz Kuryk (ORCID: https://orcid.org/0000-0003-1887-6361)
- Robert G. Ramsay (ORCID: https://orcid.org/0000-0001-5003-0433)
- Sara Roth (ORCID: https://orcid.org/0000-0002-6510-181X)
- Kasmira Wilson (ORCID: https://orcid.org/0000-0002-4601-5270)
- Anne‐Sophie W. Møller
- Toàn Pham
- Stephen Q. Wong (ORCID: https://orcid.org/0000-0002-7335-2168)
- Joseph C. Kong (ORCID: https://orcid.org/0000-0002-1392-2480)
- Shienny Sampurno (ORCID: https://orcid.org/0000-0002-4442-5508)
- Sanjeev Deva (ORCID: https://orcid.org/0000-0002-7933-303X)
- Michael Michael (ORCID: https://orcid.org/0000-0002-0593-2662)
- Jon Amund Eriksen (ORCID: https://orcid.org/0009-0007-9987-6764)
- Cecilie Sverdrup
Institutions
- The University of Queensland (AU)
- The University of Melbourne (AU)
- Royal Brisbane and Women's Hospital (AU)
- Peter MacCallum Cancer Centre (AU)
- Auckland City Hospital (NZ)
- Targovax (Norway) (NO)
- Alfred Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Heliyon
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1016/j.heliyon.2024.e41364
- Citations
- 3
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Peter MacCallum Cancer Centre